Arrowhead focuses on developing medicines that treat intractable diseases by using ribonucleic acid interference mechanism.Read more
President & CEO
Arrowhead's revenue is the ranked 3rd among it's top 10 competitors. The top 10 competitors average 2.7B. Over the last four quarters, Arrowhead's revenue has decreased by 15.3%. Specifically, in Q2 2022's revenue was $32.4M; in Q1 2022, it was $151.8M; in Q4 2021, it was $27.4M; in Q3 2021, Arrowhead's revenue was $38.3M.